BioCryst Pharmaceuticals vs Insmed
BCRX and INSM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BCRX and INSM compare
Insmed is the larger company, worth 14 times as much as BioCryst Pharmaceuticals ($26.6B against $1.9B).
Insmed grew revenue faster over the last twelve months (240% versus 60.3% for BioCryst Pharmaceuticals).
BioCryst Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −37.4% compared with −39.9% at Insmed.
BioCryst Pharmaceuticals scores higher on the StockData Score (9 against 8 for Insmed), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BCRX | INSM |
|---|---|---|
| Size and price | ||
| Market cap | $1.9B | $26.6B |
| Share price | $7.61 | $121.16 |
| Change, 1 year | 6.0% | −37.7% |
| Change, 5 years | −36.0% | 298% |
| Beta (5Y) | 0.79 | 0.76 |
| Employees | 435 | 1,664 |
| StockData Score | ||
| Total score | 9 (better) | 8 |
| Valuation score | 1 (better) | 0 |
| Growth score | 4 (better) | 3 |
| Performance score | 2 | 2 |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.0× (better) | 17.5× |
| P/B | – | 36.6× |
| P/FCF | 5.3× | – |
| FCF yield | 18.8% (better) | −2.4% |
| Fair value | – | $60.58 |
| Margin of safety | – | −100% |
| Growth | ||
| Revenue growth (TTM) | 60.3% | 240% (better) |
| Revenue growth, 5Y average | 118% (better) | 29.8% |
| Profitability | ||
| Gross margin | 97.9% (better) | 84.4% |
| Operating margin | −30.1% (better) | −37.1% |
| Net margin | −37.4% (better) | −39.9% |
| FCF margin | 38.0% (better) | −41.3% |
| Return on equity | – | −72.5% |
| Financial health | ||
| Debt / equity | – | 0.76 |
| Interest coverage | −3.8× (better) | −6.9× |
| Current ratio | 2.71 | 2.86 (better) |
| Altman Z-score | −3.13 | 7.36 (better) |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 103% | 102% |
| Held by insiders | 1.9% | 0.89% |
| Insider net buying, 12 months | −$4.1M (better) | −$133M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 11.0% | 6.5% |
Go deeper
- BCRX stock overview
- BCRX income statement
- BCRX valuation and score
- INSM stock overview
- INSM income statement
- INSM valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.